Cochlear Limited (ASX: COH) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Cochlear Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Cochlear Limited (ASX: COH)
Latest News
⏸️ ASX Shares
Why a recession shouldn't matter for the ASX share market
⏸️ Investing
3 ASX blue-chip shares I would buy at today's prices
⏸️ ASX Shares
3 strong ASX blue chip shares with stellar long term growth prospects
How to invest
How to turn $20,000 into $350,000 in 10 years with ASX shares
⏸️ ASX Shares
Why I would buy these blue chip ASX shares for the long term
Share Market News
Here are the highlights of this ASX reporting season
How to invest
Why it may not be too late to chase ASX reporting season record breakers
Share Market News
ASX 200 rises 0.8%, Treasury Wine Estate shares turn sour
Share Gainers
Why Cochlear, Kogan, Megaport, & Northern Star shares are charging higher
Share Market News
ASX 200 up 0.2%: Westpac cancels dividend, Treasury Wine hammered, Coles impresses
Share Market News
Cochlear share price on watch after COVID-19 profit collapse
Share Market News
Cochlear share price drops following patent infringement case update
Frequently Asked Questions
-
Yes, Cochlear Ltd has historically paid two fully franked dividends a year.
-
Cochlear Ltd generally pays its dividends in April and October.
-
Cochlear Ltd listed on the ASX on 4 December 1995.
COH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Cochlear Limited
Cochlear Ltd (ASX: COH) is the world's leading cochlear implant device manufacturer with around half of global market share.
The company was founded in Australia in 1983 to commercialise implants pioneered by Melbourne researcher Dr Graeme Clark, but later became a separate entity.
Developed markets contribute the bulk of Cochlear's group revenue with cochlear implants the standard of care for children with severe to profound hearing loss. The company is also catering for a growing cohort of seniors when standard hearing aid technology loses its effectiveness.
Cochlear's main products include cochlear implants, bone-anchored hearing devices, and associated sound processors. The vast majority of Cochlear's revenue is derived from overseas, with the US and Europe by far the company's two largest markets.
